GlobeNewswire by notified

Munich Re upscaling human rights due diligence using Verisk’s ESG risk analytics

Share

LONDON, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Munich Re, a leading global provider of reinsurance, primary insurance and insurance-related risk solutions, has selected Verisk’s global risk analytics business, Verisk Maplecroft, to help it enhance human rights due diligence across the entire enterprise.

Using Verisk Maplecroft’s world leading Human Rights Risk Indices, which identify exposure to 31 civil, political and labour rights risks at national and subnational levels in 198 countries, Munich Re will upscale its ability to undertake global operational risk assessments, alongside factoring the data into its underwriting and investment decisions.

 “Munich Re has always been committed to observe its duty of care on human rights along the value chain and has strived to prevent potential adverse impact on human rights arising from its business operations,” says Silke Jolowicz, Head of Sustainability at Munich Re. “To meet our strong internal requirements and the increasing legal obligations facing global business today we have decided to work with Verisk Maplecroft whose data will help us achieve these aims.”

Verisk Maplecroft has been measuring and analysing human rights risks for over 15 years. Its Human Rights Dataset is the only structured set of analytics covering the full range of rights the world over and is recognised as the benchmark for excellence in assessing these risks. The data has long been used by multinationals managing human rights risks in their operations and supply chains, and by asset managers and banks assessing and addressing their human rights risk exposure across complex global investment and lending portfolios. Adoption by insurers is the next step.

“As sustainability and ESG continue to quickly move more central into insurer’s strategic and operational thinking, we’re seeing increased attention from companies in the sector into how they can better manage human rights due diligence processes and wider ESG issues, such as climate change,” says Verisk Maplecroft President Matt Moshiri. “Munich Re is one of the first movers in this space and we are delighted to be working with them in their efforts.”

About Verisk Maplecroft

As organisations strive to understand and adapt to a fast-moving world, Verisk Maplecroft empowers them to put the environment, human rights and political risk at the heart of their decision-making. We do this by providing unparalleled intelligence on sustainability, resilience and ESG – stitching together these disparate issues into an interconnected global view, built upon objective insight and data. By thinking ‘big picture’ we capture what matters most to our partners; making positive outcomes possible in a time of change; helping people, business and societies become stronger; creating value with values. Verisk Maplecroft is a Verisk business (Nasdaq: VRSK).

For more information visit: www.maplecroft.com

About Verisk

Verisk (Nasdaq: VRSK) provides data-driven analytic insights and solutions for the insurance and energy industries. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk empowers customers to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global issues, including climate change and extreme events as well as political and ESG topics. With offices in more than 30 countries, Verisk consistently earns certification by Great Place to Work and fosters an inclusive culture where all team members feel they belong. For more, visit Verisk.com and the Verisk Newsroom.

About Munich Re

Munich Re is one of the world’s leading providers of reinsurance, primary insurance and insurance-related risk solutions. The Group consists of the reinsurance and ERGO business segments, as well as the asset manager MEAG. Munich Re is globally active and operates in all lines of the insurance business. Since it was founded in 1880, Munich Re has been known for its unrivalled risk-related expertise and its sound financial position. It offers customers financial protection when faced with exceptional levels of damage – from the 1906 San Francisco earthquake through Hurricane Ida in 2021. Munich Re possesses outstanding innovative strength, which enables it to also provide coverage for extraordinary risks such as rocket launches, renewable energies or cyber risks. The company is playing a key role in driving forward the digital transformation of the insurance industry, and in doing so has further expanded its ability to assess risks and the range of services that it offers. Its tailor-made solutions and close proximity to its customers make Munich Re one of the world’s most sought-after risk partners for businesses, institutions, and private individuals.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Sodexo announces solid H1 Fiscal 2024 results19.4.2024 07:00:00 CEST | Press release

Issy-les-Moulineaux, April 19, 2024 Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Sodexo announces solid H1 Fiscal 2024 results Organic Revenue growth +8.5%Underlying operating profit +16.9% at constant currencies, margin up +40 bpsFiscal 2024 guidance:Organic growth now expected at the top of the +6% to +8% rangeUnderlying operating profit margin improvement confirmed at +30 to +40 bps, at constant currencies At the Board of Directors meeting held on April 18, 2024, chaired by Sophie Bellon, the Board closed the Consolidated accounts for the First half Fiscal 2024 ended February 29, 2024. First half Fiscal 2024 key figures (in million euros)H1 FISCAL 2024H1 FISCAL 2023 RESTATEDDIFFERENCEDIFFERENCE CONSTANT RATESRevenues12,10111,581 +4.5% +7.8%Organic revenue growth +8.5% +12.9%UNDERLYING OPERATING PROFIT612545+12.3%+16.9%UNDERLYING OPERATING PROFIT MARGIN5.1%4.7%+40bps+40bpsOther operating income & expenses30(36)OPERATING PROFIT642509+26.1%+30.1%Net financial expense(46)(43)Tax cha

Pluxee delivers strong performance in the First Half and raises Fiscal 2024 Organic revenue growth and Recurring EBITDA margin objectives19.4.2024 07:00:00 CEST | Press release

First Half Fiscal 2024 Results Issy-les-Moulineaux, France – April 19, 2024 First Half Fiscal 2024 highlights Successful spin-off and listing on Euronext Paris on February 1, 2024 Organic revenue growth of +24% incl. +26% in Q2, reflecting buoyant performance across all regions Strong Recurring EBITDA at €201 million, i.e. +28% organic growth; 34.4% margin at constant rates Net profit of €68 million reflecting higher one-time items, mostly spin-off related Recurring free cash flow of €228 million, with strong Recurring Cash conversion of 113%Net cash position of €1,065 million, increasing by €206 million since August 31, 2023Fiscal 2024 financial objectives raised: Organic revenue growth expected between 15% to 17% and Recurring EBITDA margin expected at 35% at least including standalone costs at constant rates, while reaffirming all mid-term targets First Half Fiscal 2024 key figures (in millions of euros)H1 FY 2024H1 FY 2023Variation (%)Variation at constant rate (%)Total revenues593

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer19.4.2024 07:00:00 CEST | Press release

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGFR and PD-L1 biomarkers in people with early-stage NSCLC to inform adjuvant therapy selection Basel, 19 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and on

Evs Invites Its Shareholders to the Ordinary General Meeting and an Extraordinary General Meeting on May 21, 202419.4.2024 06:30:00 CEST | Press release

Publication on April 19, 2024, at 6:30 am before market opening Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS INVITES ITS SHAREHOLDERS TO THE ORDINARY GENERAL MEETING AND AN EXTRAORDINARY GENERAL MEETING ON MAY 21, 2024 EVS Broadcast Equipment, leading provider of live video production systems, published today the invitation to its Ordinary General Meeting, to be held on May 21, 2024, at 11 am, at its registered office in Liège, to deliberate on the agenda available on the website of the company (see link below). Aside from the usual topics, including the 2023 annual and sustainability reports, the Board of Directors will propose to the Shareholders to approve the following resolutions: The payment of a total gross dividend of EUR 1.10 per share (including the interim dividend of EUR 0.50 paid in November 2023);A profit-sharing plan in the form of a grant of 36 EVS shares for each EVS employee, in proportion to

Icelandic Salmon - Annual Report for 202319.4.2024 06:00:00 CEST | Press release

Bíldudalur, 19 April 2023 Icelandic Salmon AS (Euronext Growth Oslo and First North Iceland: ISLAX) has today published its integrated Annual Report for 2023, including sustainability reporting and complete annual accounts with notes. The report is attached and available on the company‘s website: https://arnarlax.is/investors/ “In 2023, Icelandic Salmon supplied the world markets with a record-breaking 17,919 tonnes of salmon, thanks to the dedicated work of our employees. Despite facing many challenges this year - including macroeconomic changes, geopolitical tensions, and biological obstacles – we prioritised the health and wellbeing of our fish. Looking ahead, we are committed to sustaining this priority while growing our operations," Bjørn Hembre, CEO of Icelandic Salmon and Arnarlax says. In Bjørn‘s letter, which in included in the report, he writes: “Salmon farming holds great promise for Iceland, in terms of future jobs and economic growth. During the past few years, we have see

HiddenA line styled icon from Orion Icon Library.Eye